Table 3.
Mortality in patients with and without baseline renal insufficiency
| Patient group | Mortality at 14 wk [no./total (%)] |
P value | |
|---|---|---|---|
| Voriconazole | Amphotericin B/fluconazole | ||
| All patients | 88/248 (36) | 51/122 (42) | 0.23 |
| Without baseline renal insufficiency | 68/207 (33) | 40/105 (38) | 0.36 |
| Baseline renal insufficiency | 20/41 (49)a | 11/17 (65)b | 0.27 |
| Moderate renal insufficiency | 15/32 (47) | 7/13 (54) | 0.67 |
| Severe renal insufficiency | 5/9 (56) | 4/4 (100) | 0.11 |
| Candidemia-related mortality | 5/41 (12) | 4/17 (24) | 0.28 |
a
P = 0.051 compared to patients without baseline renal insufficiency randomized to voriconazole.
b
P = 0.039 compared to patients without baseline renal insufficiency randomized to amphotericin B/fluconazole.